Seres Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Seres Therapeutics, Inc. (MCRB) reported Net Income (Loss) Available to Common Stockholders, Diluted of $4.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $4.58M.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$19.91M, a 160.93% decline year-over-year.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$15.34M.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $8.20M, a 90.76% decline year-over-year.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $5.70M, a 4088.24% increase from fiscal 2024.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was $136.00K.
- Seres Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$113.72M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.58M 10-Q · filed 2026-08-05 | -$15.33M 10-Q · filed 2026-08-05 | -$30.67M derived: sum of 3 quarters · filed 2026-08-05 | -$22.46M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$19.91M 10-Q · filed 2026-05-05 | -$35.25M derived: sum of 2 quarters · filed 2026-05-05 | -$27.04M derived: sum of 3 quarters · filed 2026-05-05 | -$46.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$15.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$7.13M derived: sum of 2 quarters · filed 2026-03-12 | -$26.99M derived: sum of 3 quarters · filed 2026-08-05 | $5.70M 10-K · filed 2026-03-12 |
| 2025-09-30 | $8.20M 10-Q · filed 2025-11-05 | -$11.65M derived: sum of 2 quarters · filed 2026-08-05 | $21.03M 10-Q · filed 2025-11-05 | $5.39M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$19.86M 10-Q · filed 2026-08-05 | $12.83M 10-Q · filed 2026-08-05 | -$2.81M derived: sum of 3 quarters · filed 2026-08-05 | $85.97M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $32.68M 10-Q · filed 2026-05-05 | $17.05M derived: sum of 2 quarters · filed 2026-05-05 | $105.82M derived: sum of 3 quarters · filed 2026-05-05 | $72.95M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$15.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $73.14M derived: sum of 2 quarters · filed 2026-03-12 | $40.27M derived: sum of 3 quarters · filed 2026-03-12 | $136.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $88.78M 10-Q · filed 2025-11-05 | $55.91M derived: sum of 2 quarters · filed 2025-11-05 | $15.77M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$32.87M 10-Q · filed 2025-08-06 | -$73.00M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | -$40.13M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | -$113.72M 10-K · filed 2026-03-12 | |||
| 2023-06-30 | $46.55M 10-Q · filed 2024-08-13 | -$24.62M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$71.17M 10-Q · filed 2023-05-09 | |||
| 2022-09-30 | -$60.00M 10-Q · filed 2022-11-02 | -$124.74M derived: sum of 2 quarters · filed 2023-08-08 | -$181.36M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | -$64.73M 10-Q · filed 2023-08-08 | -$121.36M 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | -$56.62M 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $68.22M 10-Q · filed 2022-11-02 | -$15.58M 10-Q · filed 2022-11-02 | ||
| 2020-09-30 | -$30.28M 10-Q · filed 2021-11-10 | -$70.88M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |